MedTrace Logo

Clinical Use of Pathogen Reduced Red Blood Cell Suspension

NCT03426553 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-12-24

No results posted yet for this study

Summary

The aim of the study is to evaluate the effectiveness and safety of the application of pathogen inactivated RBC suspension in children with oncological and hematological diseases.

Conditions

Interventions

BIOLOGICAL

Riboflavin+UV RBC

35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology

BIOLOGICAL

irradiated RBC

35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension

Sponsors & Collaborators

  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology

    lead OTHER

Principal Investigators

  • Pavel Trakhtman, PhD · Federal Research Center for pediatric hematology, oncology and immunology

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2018-09-17
Completion
2018-12-17

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426553 on ClinicalTrials.gov